A Study of LY3200882 in Participants With Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

November 21, 2016

Primary Completion Date

February 27, 2020

Study Completion Date

August 31, 2026

Conditions
Solid Tumor
Interventions
DRUG

LY3200882

Administered orally

DRUG

LY3300054

Administered intravenously

DRUG

Gemcitabine

Administered intravenously

DRUG

nab-Paclitaxel

Administered intravenously

DRUG

Cisplatin

Administered intravenously

RADIATION

Intensity Modulated Radiotherapy

Trial Locations (18)

2010

St Vincent's Hospital Sydney, Sydney

2298

Calvary Mater Newcastle, Newcastle

4120

Greenslopes Private Hospital, Greenslopes

10021

Weill Cornell Medical College, New York

12203

Charité Campus Virchow-Klinikum, Berlin

20089

Istituto Clinico Humanitas, Rozzano

28041

Hospital Universitario 12 de Octubre, Madrid

37134

Ospedale Policlinico Giambattista Rossi, Borgo Roma, Verona

40202

University of Louisville, Louisville

46010

Hospital Clínico Universitario de Valencia, Valencia

59037

CHRU de Lille, Lille

75475

Hopital Saint-Louis, Paris

77030

University of Texas MD Anderson Cancer Center, Houston

94805

Gustave Roussy, Villejuif

97080

Universitätsklinikum Würzburg A. ö. R., Würzburg

Unknown

Princess Margaret Hospital (Ontario), Lai Chi Kok

104-0045

National Cancer Center Hospital, Chuo-Ku

08035

Hospital Universitari Vall d'Hebron, Barcelona

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY